Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism.

Jeong MY, Lin YH, Wennersten SA, Demos-Davies KM, Cavasin MA, Mahaffey JH, Monzani V, Saripalli C, Mascagni P, Reece TB, Ambardekar AV, Granzier HL, Dinarello CA, McKinsey TA.

Sci Transl Med. 2018 Feb 7;10(427). pii: eaao0144. doi: 10.1126/scitranslmed.aao0144.

2.

Histone deacetylase adaptation in single ventricle heart disease and a young animal model of right ventricular hypertrophy.

Blakeslee WW, Demos-Davies KM, Lemon DD, Lutter KM, Cavasin MA, Payne S, Nunley K, Long CS, McKinsey TA, Miyamoto SD.

Pediatr Res. 2017 Oct;82(4):642-649. doi: 10.1038/pr.2017.126. Epub 2017 Jun 21.

3.

Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension.

Aiello RJ, Bourassa PA, Zhang Q, Dubins J, Goldberg DR, De Lombaert S, Humbert M, Guignabert C, Cavasin MA, McKinsey TA, Paralkar V.

J Pharmacol Exp Ther. 2017 Feb;360(2):267-279. doi: 10.1124/jpet.116.237933. Epub 2016 Dec 7.

4.

Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput, high content imaging.

Reid BG, Stratton MS, Bowers S, Cavasin MA, Demos-Davies KM, Susano I, McKinsey TA.

J Mol Cell Cardiol. 2016 Aug;97:106-13. doi: 10.1016/j.yjmcc.2016.04.015. Epub 2016 Apr 27.

5.

Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series).

Cavasin MA, Stenmark KR, McKinsey TA.

Pulm Circ. 2015 Mar;5(1):63-72. doi: 10.1086/679700. Review.

6.

Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition.

Cavasin MA, Demos-Davies KM, Schuetze KB, Blakeslee WW, Stratton MS, Tuder RM, McKinsey TA.

J Transl Med. 2014 Nov 26;12:314. doi: 10.1186/s12967-014-0314-y.

7.

Endoplasmic reticulum stress effector CCAAT/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcification.

Miyazaki-Anzai S, Masuda M, Demos-Davies KM, Keenan AL, Saunders SJ, Masuda R, Jablonski K, Cavasin MA, Kendrick J, Chonchol M, McKinsey TA, Levi M, Miyazaki M.

J Am Heart Assoc. 2014 Jun 24;3(3):e000949. doi: 10.1161/JAHA.114.000949.

8.

HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling.

Demos-Davies KM, Ferguson BS, Cavasin MA, Mahaffey JH, Williams SM, Spiltoir JI, Schuetze KB, Horn TR, Chen B, Ferrara C, Scellini B, Piroddi N, Tesi C, Poggesi C, Jeong MY, McKinsey TA.

Am J Physiol Heart Circ Physiol. 2014 Jul 15;307(2):H252-8. doi: 10.1152/ajpheart.00149.2014. Epub 2014 May 23.

9.

Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes.

Williams SM, Golden-Mason L, Ferguson BS, Schuetze KB, Cavasin MA, Demos-Davies K, Yeager ME, Stenmark KR, McKinsey TA.

J Mol Cell Cardiol. 2014 Feb;67:112-25. doi: 10.1016/j.yjmcc.2013.12.013. Epub 2013 Dec 26.

10.

BET acetyl-lysine binding proteins control pathological cardiac hypertrophy.

Spiltoir JI, Stratton MS, Cavasin MA, Demos-Davies K, Reid BG, Qi J, Bradner JE, McKinsey TA.

J Mol Cell Cardiol. 2013 Oct;63:175-9. doi: 10.1016/j.yjmcc.2013.07.017. Epub 2013 Aug 9.

11.

Roles of histone deacetylation and AMP kinase in regulation of cardiomyocyte PGC-1α gene expression in hypoxia.

Ramjiawan A, Bagchi RA, Blant A, Albak L, Cavasin MA, Horn TR, McKinsey TA, Czubryt MP.

Am J Physiol Cell Physiol. 2013 Jun 1;304(11):C1064-72. doi: 10.1152/ajpcell.00262.2012. Epub 2013 Mar 20.

12.

Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.

Cavasin MA, Demos-Davies K, Horn TR, Walker LA, Lemon DD, Birdsey N, Weiser-Evans MC, Harral J, Irwin DC, Anwar A, Yeager ME, Li M, Watson PA, Nemenoff RA, Buttrick PM, Stenmark KR, McKinsey TA.

Circ Res. 2012 Mar 2;110(5):739-48. doi: 10.1161/CIRCRESAHA.111.258426. Epub 2012 Jan 26.

13.

Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.

Lemon DD, Horn TR, Cavasin MA, Jeong MY, Haubold KW, Long CS, Irwin DC, McCune SA, Chung E, Leinwand LA, McKinsey TA.

J Mol Cell Cardiol. 2011 Jul;51(1):41-50. doi: 10.1016/j.yjmcc.2011.04.005. Epub 2011 Apr 23.

14.

Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats.

Cavasin MA, Semus H, Pitts K, Peng Y, Sandoval J, Chapo J, Plato CF.

Can J Physiol Pharmacol. 2010 Jun;88(6):636-43. doi: 10.1139/Y10-038.

15.

Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension.

Liao TD, Yang XP, Liu YH, Shesely EG, Cavasin MA, Kuziel WA, Pagano PJ, Carretero OA.

Hypertension. 2008 Aug;52(2):256-63. doi: 10.1161/HYPERTENSIONAHA.108.112706. Epub 2008 Jun 9.

16.

Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarction.

Xu J, Carretero OA, Lin CX, Cavasin MA, Shesely EG, Yang JJ, Reudelhuber TL, Yang XP.

Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1900-7. Epub 2007 Jun 22.

17.

Decreased endogenous levels of Ac-SDKP promote organ fibrosis.

Cavasin MA, Liao TD, Yang XP, Yang JJ, Carretero OA.

Hypertension. 2007 Jul;50(1):130-6. Epub 2007 Apr 30.

19.

Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function.

Cavasin MA, Tao ZY, Yu AL, Yang XP.

Am J Physiol Heart Circ Physiol. 2006 May;290(5):H2043-50. Epub 2005 Dec 16.

20.

Gender differences in cardiac function during early remodeling after acute myocardial infarction in mice.

Cavasin MA, Tao Z, Menon S, Yang XP.

Life Sci. 2004 Sep 17;75(18):2181-92.

PMID:
15325844
21.

Role of nitric oxide in the renal hemodynamic response to unilateral nephrectomy.

Sigmon DH, Gonzalez-Feldman E, Cavasin MA, Potter DL, Beierwaltes WH.

J Am Soc Nephrol. 2004 Jun;15(6):1413-20.

22.

Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.

Rasoul S, Carretero OA, Peng H, Cavasin MA, Zhuo J, Sanchez-Mendoza A, Brigstock DR, Rhaleb NE.

J Hypertens. 2004 Mar;22(3):593-603.

PMID:
15076166
23.

Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP.

Cavasin MA, Rhaleb NE, Yang XP, Carretero OA.

Hypertension. 2004 May;43(5):1140-5. Epub 2004 Mar 22.

24.
25.

Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats.

Cingolani OH, Yang XP, Cavasin MA, Carretero OA.

Hypertension. 2003 Feb;41(2):249-54.

26.

Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction.

Cavasin MA, Sankey SS, Yu AL, Menon S, Yang XP.

Am J Physiol Heart Circ Physiol. 2003 May;284(5):H1560-9. Epub 2003 Jan 30.

27.

Long-term effects of selective and nonselective endothelin receptor antagonists in mice with heart failure.

Cavasin MA, Carretero OA, Yang F, Oja-Tebbe N, Peng H, Yang XP.

J Card Fail. 2002 Aug;8(4):254-61.

PMID:
12397574
28.

Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice.

Yang XP, Liu YH, Mehta D, Cavasin MA, Shesely E, Xu J, Liu F, Carretero OA.

Circ Res. 2001 May 25;88(10):1072-9.

29.

Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure.

Cavasin MA, Yang XP, Liu YH, Mehta D, Karumanchi R, Bulagannawar M, Carretero OA.

J Cardiovasc Pharmacol. 2000 Oct;36(4):472-80.

PMID:
11026648

Supplemental Content

Loading ...
Support Center